2 peer-reviewed articles indexed
This Phase III randomized controlled trial investigated pembrolizumab combined with standard chemotherapy in 634 patients with early triple-negative breast cancer. The combination therapy demonstrated...
KRAS mutations, present in 95% of pancreatic ductal adenocarcinomas, have historically been considered undruggable. This study demonstrates in vivo CRISPR-Cas9 correction of KRASG12D mutations using l...